Spinal muscular atrophy - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Spinal muscular atrophy - Pipeline Insight, 2021,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Spinal muscular atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Spinal muscular atrophy: Overview
Spinal muscular atrophy (SMA) is a group of inherited disorders characterized by a loss of certain nerve cells in the spinal cord called motor neurons or anterior horn cells. Motor neurons receive the nerve impulses transmitted from the brain to the spinal cord (brainstem) and, in turn, transmit the impulses to the muscle via the peripheral nerves. The loss of motor neurons leads to progressive muscle weakness and muscle wasting (atrophy) in muscles closest to the trunk of the body (proximal muscles) such as the shoulders, hips and back. These muscles are necessary for crawling, walking, sitting up and head control. The more severe types of SMA can affect muscles involved in feeding, swallowing and breathing.
'Spinal muscular atrophy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spinal muscular atrophy pipeline landscape is provided which includes the disease overview and Spinal muscular atrophy treatment guidelines. The assessment part of the report embraces, in depth Spinal muscular atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal muscular atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Spinal muscular atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spinal muscular atrophy Emerging Drugs
Further product details are provided in the report……..
Spinal muscular atrophy: Therapeutic Assessment
This segment of the report provides insights about the different Spinal muscular atrophy drugs segregated based on following parameters that define the scope of the report, such as:
Spinal muscular atrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal muscular atrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal muscular atrophy drugs.
Spinal muscular atrophy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Spinal muscular atrophy - Pipeline Insight, 2021,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Spinal muscular atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Spinal muscular atrophy: Overview
Spinal muscular atrophy (SMA) is a group of inherited disorders characterized by a loss of certain nerve cells in the spinal cord called motor neurons or anterior horn cells. Motor neurons receive the nerve impulses transmitted from the brain to the spinal cord (brainstem) and, in turn, transmit the impulses to the muscle via the peripheral nerves. The loss of motor neurons leads to progressive muscle weakness and muscle wasting (atrophy) in muscles closest to the trunk of the body (proximal muscles) such as the shoulders, hips and back. These muscles are necessary for crawling, walking, sitting up and head control. The more severe types of SMA can affect muscles involved in feeding, swallowing and breathing.
'Spinal muscular atrophy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spinal muscular atrophy pipeline landscape is provided which includes the disease overview and Spinal muscular atrophy treatment guidelines. The assessment part of the report embraces, in depth Spinal muscular atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal muscular atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spinal muscular atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Spinal muscular atrophy.
This segment of the Spinal muscular atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spinal muscular atrophy Emerging Drugs
- Apitegromab: Scholar Rock
- BIIB110: Biogen
Further product details are provided in the report……..
Spinal muscular atrophy: Therapeutic Assessment
This segment of the report provides insights about the different Spinal muscular atrophy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Spinal muscular atrophy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Spinal muscular atrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal muscular atrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal muscular atrophy drugs.
Spinal muscular atrophy Report Insights
- Spinal muscular atrophy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Spinal muscular atrophy drugs?
- How many Spinal muscular atrophy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinal muscular atrophy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spinal muscular atrophy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spinal muscular atrophy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Scholar Rock
- Biogen
- Astellas Pharma
- AurimMed Pharma
- Alcyone Therapeutics
- Kowa
- Helixmith
- Novartis
- PTC Therapeutics
- AndroScience Corporation
- Catalyst Pharmaceuticals
- Apitegromab
- BIIB 110
- Reldesemtiv
- ACTX 401
- Sodium valproate
- VM 101
- BVS 857
- NVS-SM1
- SMN-C1
- ASCJ 9
Introduction
Executive Summary
Spinal muscular atrophy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Sodium valproate: Kowa
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Apitegromab: Scholar Rock
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BIIB 110: Biogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
SMN-C1: PTC Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Spinal muscular atrophy Key Companies
Spinal muscular atrophy Key Products
Spinal muscular atrophy- Unmet Needs
Spinal muscular atrophy- Market Drivers and Barriers
Spinal muscular atrophy- Future Perspectives and Conclusion
Spinal muscular atrophy Analyst Views
Spinal muscular atrophy Key Companies
Appendix
Executive Summary
Spinal muscular atrophy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Sodium valproate: Kowa
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Apitegromab: Scholar Rock
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BIIB 110: Biogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
SMN-C1: PTC Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Spinal muscular atrophy Key Companies
Spinal muscular atrophy Key Products
Spinal muscular atrophy- Unmet Needs
Spinal muscular atrophy- Market Drivers and Barriers
Spinal muscular atrophy- Future Perspectives and Conclusion
Spinal muscular atrophy Analyst Views
Spinal muscular atrophy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Spinal muscular atrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Spinal muscular atrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Spinal muscular atrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Spinal muscular atrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products